Prevention & lipids

Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk

J Am Coll CardiolPublished Randomised controlled trial

Authors' conclusion

Oral NLRP3 inhibition with ruvonoflast significantly reduced hsCRP with concurrent reductions in inflammatory biomarkers in participants with elevated inflammatory risk.

Study context

Population
Individuals with high-sensitivity C-reactive protein (hsCRP) ≥2.5 mg/L and BMI ≥30 to ≤40 kg/m², plus dyslipidemia, hypertension or T2DM, on a 2,000 kcal/d diet59 completed
Participants
63 individuals
Comparison
Oral ruvonoflast vs placebo
  • Ruvonoflastn = 40
  • Placebon = 23reference
Primary endpoint
Change in hsCRP (ratio to baseline)
Follow-up
Day 28
Methodological detailsdouble-blind, placebo-controlled, Phase 1b
  • Double-blind
  • Placebo-controlled
  • Phase 1b

Primary result

As reported in the abstract

hsCRP reduction

Ruvonoflast

82.2%

geometric least-squares mean reduction · 95% CI 75.9%–86.8%

Placebo

37.2%

geometric least-squares mean reduction · 95% CI 7.0%–57.6%

Posterior probability of superiority of ruvonoflast over placebo (Bayesian ANCOVA)
>99%

Secondary outcomes

hsCRP over time · from Day 3 onward

Between-group differences favouring ruvonoflast significant
P ≤ 0.001
hsCRP returned to baseline 7 days after treatment discontinuation

Interleukin-6 and fibrinogen · Day 28

Significantly lowered with ruvonoflast vs placebo
P < 0.001

Body weight · Day 28

Comparable mean percentage body weight reductions between groups

Safety

OutcomeRuvonoflastPlacebo
Discontinuation due to transient, reversible treatment-emergent adverse events10%0 events

Discontinuation due to transient, reversible treatment-emergent adverse events

Serious treatment-emergent adverse events similar between groups

Original publication

Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk. J Am Coll Cardiol. Published 26 May 2026. doi:10.1016/j.jacc.2026.05.014

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.